| Literature DB >> 27168737 |
Christina G de Souza E Silva1, Barry A Franklin2, Daniel E Forman3, Claudio Gil S Araújo1.
Abstract
OBJECTIVE: To assess the influence of age on the error of estimate (EE) of maximal oxygen uptake (VO2max) using sex and population specific-equations in cycle ergometer exercise testing, since estimated VO2 max is associated with a substantial EE, often exceeding 20%, possibly due to intrinsic variability of mechanical efficiency.Entities:
Keywords: Aging; Cardiopulmonary exercise testing; Error of measurement
Year: 2016 PMID: 27168737 PMCID: PMC4854950 DOI: 10.11909/j.issn.1671-5411.2016.02.010
Source DB: PubMed Journal: J Geriatr Cardiol ISSN: 1671-5411 Impact factor: 3.327
Major demographics and CPX results according to age-groups - men (n = 1262).
| Age groups | Younger ( | Middle-aged ( | Older ( | |
| Characteristics | ||||
| Age (yrs) | 29 ± 5 | 49 ± 7 | 69 ± 7 | < 0.01 |
| Weight (kg) | 86.1 ± 16.6 | 88.3 ± 15.0 | 82.2 ± 13.6 | < 0.01 |
| Height (cm) | 177.2 ± 6.5 | 176.9 ± 6.2 | 171.9 ± 6.9 | < 0.01* |
| BMI (kg/m2) | 27.4 ± 5.0 | 28.2 ± 4.3 | 27.8 ± 3.9 | > 0.05 |
| Predicted VO2max [mL·(kg·min)−1] | 44.1 ± 2.6 | 33.2 ± 4.0 | 21.8 ± 3.7 | < 0.01 |
| Predicted HRmax (bpm) | 188 ± 3 | 174 ± 5 | 159 ± 5 | < 0.01 |
| β -blocker usage (%) | 6.5 | 21.2 | 41.3 | |
| CPX Results | ||||
| Duration (min) | 10 ± 2 | 10 ± 2 | 9 ± 3 | < 0.01# |
| HRmax (bpm) | 184 ± 11 | 166 ± 18 | 135 ± 24 | < 0.01 |
| HRmax measured/predicted (%) | 98.0 ± 6.0 | 95.3 ± 9.5 | 84.9 ± 14.0 | < 0.05 |
| Maximum workload (Watts) | 229 ± 57 | 199 ± 5.9 | 110 ± 43 | < 0.01 |
| Maximum RER | 1.14 ± 0.10 | 1.14 ± 0.09 | 1.11 ± 0.13 | < 0.01* |
| Measured VO2max [mL·(kg·min)−1] | 38.3 ± 9.5 | 32.5 ± 9.2 | 21.4 ± 7.0 | < 0.01 |
| Measured/predicted VO2max (%) ) | 86.9 ± 21.9 | 98.1 ± 26.1 | 98.5 ± 28.7 | < 0.01€ |
| Estimated VO2max [mL·(kg·min)−1] | 36.4 ± 8.2 | 28.4 ± 7.2 | 21.6 ± 5.7 | < 0.01 |
| Error of estimate [mL·(kg·min)−1] | 1.9 ± 4.1 | 0.6 ± 3.1 | -0.2 ± 2.7 | < 0.01 |
| Percent error (%E) | 3.8 ± 10.5 | 0.4 ± 10.3 | -4.2 ± 16.6 | < 0.01 |
*non significant when comparing Younger and Middle-aged groups; #significant when comparing Middle-aged and Older groups; €non significant when comparing Middle-aged and Older groups. BMI: Body Mass Index; CPX: cardiopulmonary exercise testing; HR: heart rate; RER: respiratory exchange ratio.
Major demographics and CPX results according to age-groups – women (n = 588).
| Age groups | Younger ( | Middle-aged ( | Older ( | |
| Characteristics | ||||
| Age (yrs) | 28 ± 5 | 48 ± 7 | 70 ± 7 | < 0.01 |
| Weight (kg) | 63.5 ± 12.8 | 66.7 ± 12.2 | 69.6 ± 12.8 | < 0.05* |
| Height (cm) | 164.0 ± 5.6 | 163.7 ± 6.2 | 158.9 ± 5.9 | < 0.01* |
| BMI (kg/m2) | 23.5 ± 4.4 | 24.9 ± 4.5 | 27.6 ± 5.0 | < 0.05 |
| Predicted VO2max [mL·(kg·min)−1] | 38.2 ± 3.2 | 30.4 ± 2.8 | 22.1 ± 2.8 | < 0.01 |
| Predicted HRmax (bpm) | 188 ± 4 | 174 ± 5 | 159 ± 5 | < 0.01 |
| β -blocker usage (%) | 4.0 | 42.6 | 33.6 | |
| CPX Results | ||||
| Duration (min) | 9 ± 2 | 10 ± 3 | 7 ± 2 | < 0.01* |
| HRmax (bpm) | 184 ± 10 | 166 ± 17 | 137 ± 24 | < 0.01 |
| HRmax measured/predicted (%) | 97.6 ± 4.9 | 95.0 ± 9.3 | 86.1 ± 13.7 | < 0.01* |
| Maximum workload (Watts) | 136 ± 34 | 123 ± 42 | 67 ± 22 | < 0.01 |
| Maximum RER | 1.15 ± 0.08 | 1.15 ± 0.12 | 1.15 ± 0.11 | > 0.05 |
| Measured VO2max [mL·(kg·min)−1) | 29.9 ± 7.3 | 26.2 ± 8.4 | 15.8 ± 4.5 | < 0.01 |
| Measured/predicted VO2max (%) | 78.7 ± 20.6 | 86.4 ± 26.5 | 71.5 ± 17.8 | < 0.05¢ |
| Estimated VO2max [mL·(kg·min)−1] | 28.6 ± 5.9 | 25.6 ± 6.8 | 16.6 ± 3.2 | < 0.01 |
| Error of estimate (EE) [mL·(kg·min)−1] | 1.2 ± 3.1 | 0.7 ± 2.8 | −0.8 ± 2.3 | < 0.01* |
| Percent error (%E) | 2.7 ± 10.0 | 0.5 ± 11.1 | −9.5 ± 22.4 | < 0.01* |
Data are expressed as mean ± SD. *non significant when comparing Younger and Middle-aged groups; ¢non significant when comparing Younger and Older groups. BMI: Body Mass Index; CPX: cardiopulmonary exercise testing; HR: heart rate; RER: respiratory exchange ratio.
Major clinical conditions and prescribed medications - men (n = 1262).
| Age Groups | Younger ( | Middle-aged ( | Older ( |
| Coronary artery disease | 1.9 | 14.3 | 40.1 |
| Acute myocardial infartion | 1.3 | 7.8 | 18.4 |
| Percutaneous coronary intervention | 1.3 | 10.1 | 23.8 |
| Coronary artery bypass graft | 0.0 | 4.1 | 17.0 |
| Hypertension | 7.7 | 30.5 | 55.4 |
| Dyslipidemia | 12.3 | 38.7 | 56.1 |
| Obesity | 12.3 | 17.6 | 17.2 |
| Diabetes | 0.6 | 7.5 | 17.0 |
| β-blockers | 6.5 | 21.2 | 41.3 |
| Calcium channel blocker | 1.9 | 6.4 | 16.7 |
| Angiotensin-converting enzyme inhibitor | 3.9 | 8.5 | 16.0 |
| Angiotensin receptor antagonist | 5.8 | 26.1 | 42.0 |
| Diuretic | 3.9 | 10.0 | 29.5 |
| Vasodilator | 0.6 | 3.8 | 14.2 |
| Cholesterol lowering | 6.5 | 39.5 | 67.9 |
| Antiplatelet | 3.2 | 23.7 | 59.2 |
| Antiarrhythmic | 0.6 | 3.5 | 15.6 |
Major clinical conditions and prescribed medications – women (n = 588).
| Age Groups | Younger | Middle-aged | Older |
| ( | ( | ( | |
| Coronary artery disease | 0.0 | 4.1 | 18.1 |
| Acute myocardial infartion | 0.0 | 3.0 | 6.0 |
| Percutaneous coronary intervention | 0.0 | 3.6 | 8.1 |
| Coronary artery bypass graft | 0.0 | 0.6 | 6.0 |
| Hypertension | 5.0 | 15.7 | 44.3 |
| Dyslipidemia | 4.0 | 22.5 | 46.3 |
| Obesity | 4.0 | 9.5 | 19.5 |
| Diabetes | 0.0 | 3.6 | 12.1 |
| Β-blockers | 4.0 | 13.0 | 33.6 |
| Calcium channel blocker | 2.0 | 2.7 | 18.8 |
| Angiotensin-converting enzyme inhibitor | 1.0 | 2.1 | 8.1 |
| Angiotensin receptor antagonist | 3.0 | 13.6 | 50.3 |
| Diuretic | 4.0 | 5.3 | 34.2 |
| Vasodilator | 0.0 | 0.6 | 8.7 |
| Cholesterol lowering | 0.0 | 19.8 | 61.7 |
| Antiplatelet | 0.0 | 8.3 | 40.3 |
| Antiarrhythmic | 0.0 | 5.0 | 14.8 |
Figure 1.Relationship between measured and estimated VO2max in three age-groups (younger, middle-aged, older) in men (a) and women (b).